XHL11, a novel selective EGFR inhibitor, overcomes EGFRT790M-mediated resistance in non-small cell lung cancer.

Abstract

The first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib significantly improved the therapeutic effect in non-small cell lung cancer (NSCLC) patients with EGFR mutation. However, the EGFRT790M mutation occurs and results in acquired resistance. Consequently, mutant selective third-generation EGFR TKIs represented by AZD9291 (Osimertinib) have been developed to offer more effective therapeutic treatment, but the clinical application is limited by the acquired resistance and the high costs. A series of 5-chloropyrimidine-2,4-diamine derivatives were synthesized and screened for in vitro antitumor activity on H1975 and A431 cells. XHL11 showed the strongest antineoplastic activity. Compared to AZD9291, XHL11 suppressed cellular proliferation and colony formation and induced apoptosis in H1975 cells with EGFRL858R/T790M mutation. In addition, XHL11 caused expression changes in EGFR and apoptosis-related pathways. Moreover, oral administration of XHL11 suppressed tumor progression in vivo in a H1975 subcutaneous xenograft model. These data demonstrated that XHL11 might be developed as a promising EGFR TKI for the therapeutic use of NSCLC patients.

• Authors: Yi Li, Qing-Long Yu, Tong-Fang Li, Ya-Ni Xiao, Li Zhang, Qiu-Yan Zhang, Chun-Guang Ren, Hong-Lei Xie
• Journal: European journal of pharmacology (Eur J Pharmacol) Vol. 907 Pg. 174297 (Sep 15 2021) ISSN: 1879-0712 [Electronic] Netherlands
• PMID: 34217707 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Elsevier B.V. All rights reserved.

Chemical References

• Protein Kinase Inhibitors

Topics

• Carcinoma, Non-Small-Cell Lung
• Cell Line, Tumor
• Humans
• Lung Neoplasms
• Mutation
• Protein Kinase Inhibitors (pharmacology)